A reality check of the accelerated approval of immune-checkpoint inhibitors
- 5 August 2019
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 16 (11), 656-658
- https://doi.org/10.1038/s41571-019-0260-y
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitorsNature Reviews Drug Discovery, 2018
- Reinforcing the social compromise of accelerated approvalNature Reviews Clinical Oncology, 2018